The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
CAR-T Meeting 2024 | The evidence needs in CAR-T from the patient perspective: capturing the patient experience
Lorna Warwick, BSc, Lymphoma Coalition, Toronto, Canada, comments on the evidence needs of patients receiving CAR T-cell therapy. As CAR-T is a novel therapeutic option, insufficient tools exist for monitoring and understanding the effects of the treatment on patients’ quality of life (QoL). Several projects are underway to develop and validate questionnaires and tools that will allow the patient experience to be appropriately captured. This interview took place at the EBMT-EHA 6th European CAR T-cell Meeting in Valencia, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
